Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment

Dual Diagnosis Psychosis and Substance Abuse: Short- and Middle-term Changes in Symptomatology After Visiting a Group Education Programme to Reduce Consumption of Cannabis

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00783185

Enrollment

Registered

2008-10-31

Start date

2006-01-31

Completion date

2010-01-31

Last updated

2010-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intervention, Marijuana Abuse, Psychotic Disorders

Keywords

psychotic disorders, cannabis, intervention

Brief summary

Intention of the study is to examine, if the symptomatology of dual diagnosis patients is less severe after a special indication training for reduction of cannabis consumption in comparison to unspecified trainings. Point of interest is psychopathology and consumerism.

Detailed description

Dual diagnosis patients (psychosis and cannabis abuse) account for more clinical admissions than single diagnosis patients. Cannabis misuse is a known risk factor for recurrence of psychosis. A specified intervention on the basis of a manual for schizophrenic substance abusers is administered to inpatients in a specialized unit for young schizophrenic patients in a psychiatric hospital. The control group, same indication (psychotic disorder and cannabis misuse) receives social competence training (specified for schizophrenic patients as well). Admission to groups is randomly.

Interventions

BEHAVIORALCannabis-Consumption-Reduction-Training

8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse

BEHAVIORALSocial competence Training

8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of schizophrenia and disorders with psychotic features * Misuse of cannabis during 12 months preceding admission to hospital

Exclusion criteria

* Not able to attend training twice a week for 45 minutes (concentration, attention, psychotic symptoms, agitation) * Discharge from hospital before completion of training

Design outcomes

Primary

Measure	Time frame
PANSS Positive and Negative Symptom Scale	post intervention, six months follow-up

Secondary

Measure	Time frame
Urinstatus for cannabinoids	weekly during and post intervention, follow-up

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026